At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
Donepezil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc·interventional·Posted Sep 15, 2015·Updated Mar 5, 2019
In Brief
A Phase 2 clinical trial evaluating Donepezil and Solifenacin for Dementia of Alzheimer's Type. Completed, enrolled 28 participants across 4 sites.
Detailed Summary
This is a Phase II, ascending dose study of CPC-201 in patients with dementia of Alzheimer's type to determine the optimal dose titration schedule.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDementia of Alzheimer's Type
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartOct 2015
Primary CompletionSep 2017
TodayJul 2026
First PostedSep 15, 2015
Enrollment StartOct 7, 2015
Primary CompletionSep 28, 2017
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.8 years ago
Interventions
Donepezildrug
Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
Solifenacindrug
Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.